The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

David F. Cella

Department of Medical Social Sciences

Northwestern University Feinberg School of Medicine

633 N. St

Clair - 19th Floor Chicago

USA

[email]@northwestern.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 N. St, Clair - 19th Floor Chicago, USA. 2011 - 2013
  • Correspondence & reprint requests to Dr. Cella:. 2012
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA. 2009 - 2011
  • Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, USA. 2010
  • Center on Outcomes, Research and Education, Evanston Northwestern Healthcare and Northwestern University Feinberg School of Medicine, 1001 University Place, USA. 2002 - 2008
  • National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, USA. 2008
  • Northwestern University, Evanston, USA. 2002 - 2008
  • Evanston Northwestern Healthcare & Northwestern University, 1001 University Place, Suite 100, Evanston, USA. 2002 - 2007
  • Psychiatry and Behavioral Sciences, Institute for Healthcare Studies, Feinberg School of Medicine, Northwestern University, USA. 2007
  • Institute for Health Services Research and Policy Studies, Northwestern University, Evanston, USA. 2003

References

  1. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Cella, D., Escudier, B., Rini, B., Chen, C., Bhattacharyya, H., Tarazi, J., Rosbrook, B., Kim, S., Motzer, R. Br. J. Cancer (2013) [Pubmed]
  2. Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology. Cella, D., Lai, J.S., Nowinski, C.J., Victorson, D., Peterman, A., Miller, D., Bethoux, F., Heinemann, A., Rubin, S., Cavazos, J.E., Reder, A.T., Sufit, R., Simuni, T., Holmes, G.L., Siderowf, A., Wojna, V., Bode, R., McKinney, N., Podrabsky, T., Wortman, K., Choi, S., Gershon, R., Rothrock, N., Moy, C. Neurology (2012) [Pubmed]
  3. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. Cella, D., Bushmakin, A.G., Cappelleri, J.C., Charbonneau, C., Michaelson, M.D., Motzer, R.J. Br. J. Cancer (2012) [Pubmed]
  4. The neurology quality-of-life measurement initiative. Cella, D., Nowinski, C., Peterman, A., Victorson, D., Miller, D., Lai, J.S., Moy, C. Arch. Phys. Med. Rehabil (2011) [Pubmed]
  5. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Cella, D., Rosenbloom, S.K., Beaumont, J.L., Yount, S.E., Paul, D., Hampton, D., Abernethy, A.P., Jacobsen, P.B., Syrjala, K., Von Roenn, J.H. J. Natl. Compr. Canc. Netw (2011) [Pubmed]
  6. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Cella, D. Oncologist (2011) [Pubmed]
  7. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Cella, D., Huang, H.Q., Monk, B.J., Wenzel, L., Benda, J., McMeekin, D.S., Cohn, D., Ramondetta, L., Boardman, C.H. Gynecol. Oncol. (2010) [Pubmed]
  8. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. Cella, D., Huang, H., Homesley, H.D., Montag, A., Salani, R., De Geest, K., Lee, R., Spirtos, N.M. Gynecol. Oncol. (2010) [Pubmed]
  9. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Cella, D., Michaelson, M.D., Bushmakin, A.G., Cappelleri, J.C., Charbonneau, C., Kim, S.T., Li, J.Z., Motzer, R.J. Br. J. Cancer (2010) [Pubmed]
  10. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cella, D. Cancer Treat. Rev. (2009) [Pubmed]
  11. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Cella, D., Li, J.Z., Cappelleri, J.C., Bushmakin, A., Charbonneau, C., Kim, S.T., Chen, I., Motzer, R.J. J. Clin. Oncol. (2008) [Pubmed]
  12. Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Cella, D., Land, S.R., Chang, C.H., Day, R., Costantino, J.P., Wolmark, N., Ganz, P.A. Breast Cancer Res. Treat. (2008) [Pubmed]
  13. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Cella, D., Fallowfield, L.J. Breast Cancer Res. Treat. (2008) [Pubmed]
  14. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cella, D., Viswanathan, H.N., Hays, R.D., Mendoza, T.R., Stein, K.D., Pasta, D.J., Foreman, A.J., Vadhan-Raj, S., Kallich, J.D. Cancer (2008) [Pubmed]
  15. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Cella, D., Eton, D., Hensing, T.A., Masters, G.A., Parasuraman, B. Clin. Lung. Cancer (2008) [Pubmed]
  16. Improving health-related quality of life in non-small-cell lung cancer with current treatment options. Cella, D.F., Patel, J.D. Clin. Lung. Cancer (2008) [Pubmed]
  17. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Cella, D., Gershon, R., Lai, J.S., Choi, S. Qual. Life. Res (2007) [Pubmed]
  18. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Cella, D., Yount, S., Rothrock, N., Gershon, R., Cook, K., Reeve, B., Ader, D., Fries, J.F., Bruce, B., Rose, M. Med. Care (2007) [Pubmed]
  19. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. Cella, D., Wagner, L., Cashy, J., Hensing, T.A., Yount, S., Lilenbaum, R.C. J. Natl. Cancer Inst. Monographs (2007) [Pubmed]
  20. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). Cella, D., Yount, S., Du, H., Dhanda, R., Gondek, K., Langefeld, K., George, J., Bro, W.P., Kelly, C., Bukowski, R. J. Support. Oncol (2006) [Pubmed]
  21. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?. Cella, D., Petrylak, D.P., Fishman, M., Teigland, C., Young, J., Mulani, P. Eur. Urol. (2006) [Pubmed]
  22. Quality of life and clinical decisions in chemotherapy-induced anemia. Cella, D. Oncology (Williston Park, N.Y.) (2006) [Pubmed]
  23. Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy--thrombocytopenia (FACT-Th) questionnaire. Cella, D., Beaumont, J.L., Webster, K.A., Lai, J.S., Elting, L. Support. Care. Cancer (2006) [Pubmed]
  24. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Cella, D., Fallowfield, L., Barker, P., Cuzick, J., Locker, G., Howell, A. Breast Cancer Res. Treat. (2006) [Pubmed]
  25. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. Cella, D., Herbst, R.S., Lynch, T.J., Prager, D., Belani, C.P., Schiller, J.H., Heyes, A., Ochs, J.S., Wolf, M.K., Kay, A.C., Kris, M.G., Natale, R.B. J. Clin. Oncol. (2005) [Pubmed]
  26. Defining higher order dimensions of self-reported health: further evidence for a two-dimensional structure. Cella, D., Chang, C.H., Wright, B.D., Von Roenn, J.H., Skeel, R.T. Eval. Health. Prof (2005) [Pubmed]
  27. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Cella, D., Yount, S., Sorensen, M., Chartash, E., Sengupta, N., Grober, J. J. Rheumatol. (2005) [Pubmed]
  28. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Cella, D., Kallich, J., McDermott, A., Xu, X. Ann. Oncol. (2004) [Pubmed]
  29. Quality of life considerations in patients with advanced lung cancer. Cella, D. Semin. Oncol. (2004) [Pubmed]
  30. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. Cella, D., Zagari, M.J., Vandoros, C., Gagnon, D.D., Hurtz, H.J., Nortier, J.W. J. Clin. Oncol. (2003) [Pubmed]
  31. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Cella, D., Dobrez, D., Glaspy, J. Ann. Oncol. (2003) [Pubmed]
  32. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cella, D., Pulliam, J., Fuchs, H., Miller, C., Hurd, D., Wingard, J.R., Sonis, S.T., Martin, P.J., Giles, F. Cancer (2003) [Pubmed]
  33. Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cella, D., Peterman, A., Hudgens, S., Webster, K., Socinski, M.A. Cancer (2003) [Pubmed]
  34. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cella, D., Paul, D., Yount, S., Winn, R., Chang, C.H., Banik, D., Weeks, J. Cancer Invest. (2003) [Pubmed]
  35. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. Cella, D., Eton, D.T., Fairclough, D.L., Bonomi, P., Heyes, A.E., Silberman, C., Wolf, M.K., Johnson, D.H. J. Clin. Epidemiol (2002) [Pubmed]
  36. Fatigue in cancer patients compared with fatigue in the general United States population. Cella, D., Lai, J.S., Chang, C.H., Peterman, A., Slavin, M. Cancer (2002) [Pubmed]
  37. The effects of anemia and anemia treatment on the quality of life of people with cancer. Cella, D. Oncology (Williston Park, N.Y.) (2002) [Pubmed]
  38. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Cella, D., Hughes, C., Peterman, A., Chang, C.H., Peshkin, B.N., Schwartz, M.D., Wenzel, L., Lemke, A., Marcus, A.C., Lerman, C. Health. Psychol (2002) [Pubmed]
  39. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Cella, D., Nowinski, C.J. Arch. Phys. Med. Rehabil (2002) [Pubmed]
 
WikiGenes - Universities